These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38325608)

  • 1. Trends in primary, booster, and updated COVID-19 vaccine readiness in the United States, January 2021-April 2023: Implications for 2023-2024 updated COVID-19 vaccines.
    Ihongbe TO; Kim JC; Dahlen H; Kranzler EC; Seserman K; Moffett K; Hoffman L
    Prev Med; 2024 Mar; 180():107887. PubMed ID: 38325608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
    Sane Schepisi M
    Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Kranzler EC; Ihongbe TO; Marshall MC; Denison B; Dahlen H; Hoffman B; Seserman K; Xie J; Hoffman L
    Vaccine; 2024 Jan; 42(3):410-414. PubMed ID: 38182461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
    Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
    Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults - United States, November-December 2022.
    Lu PJ; Zhou T; Santibanez TA; Jain A; Black CL; Srivastav A; Hung MC; Kriss JL; Schorpp S; Yankey D; Sterrett N; Fast HE; Razzaghi H; Elam-Evans LD; Singleton JA
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):190-198. PubMed ID: 36795677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in COVID-19 vaccination receipt and intention to vaccinate by socioeconomic characteristics and geographic area, United States, January 6 - March 29, 2021.
    Nguyen KH; Nguyen K; Corlin L; Allen JD; Chung M
    Ann Med; 2021 Dec; 53(1):1419-1428. PubMed ID: 34482788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
    Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
    Front Immunol; 2022; 13():1031852. PubMed ID: 36451833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in adolescent COVID-19 vaccination receipt and parental intent to vaccinate their adolescent children, United States, July to October, 2021.
    Nguyen KH; Nguyen K; Geddes M; Allen JD; Corlin L
    Ann Med; 2022 Dec; 54(1):733-742. PubMed ID: 35238263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
    Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
    J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.